← Back to Search

Immunotoxin

SL-401 for Chronic Myelomonocytic Leukemia

Phase 2
Waitlist Available
Research Sponsored by Stemline Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The patient has a life expectancy of >6 months.
Patient is refractory/resistant/intolerant to HMAs, or HU, or intensive chemotherapy OR patient is classified as high-risk based on the presence of morphological features, as described by the 2016 WHO prognostic system, and the clinical and molecular features described in molecularly-integrated prognostic systems, such as the GFM, MMM, and the CMML specific prognostic model (CPSS-Mol), and thus is not expected to benefit from HMAs.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through 12 months post last dose of tagraxofusp
Awards & highlights

Study Summary

This trial is testing a new drug, tagraxofusp, to see if it is safe and effective in treating patients with either chronic myelomonocytic leukemia or myelofibrosis who have not responded to other treatments.

Eligible Conditions
  • Chronic Myelomonocytic Leukemia
  • Myelofibrosis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are expected to live for at least 6 more months.
Select...
You have already tried a certain type of medication (HMAs, HU, or strong chemotherapy) but it didn't work, or your condition is classified as high-risk based on specific features identified by your doctor and various prognostic systems.
Select...
You are not able to have a stem cell transplant right away.
Select...
You cannot receive a stem cell transplant right away.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through 12 months post last dose of tagraxofusp
This trial's timeline: 3 weeks for screening, Varies for treatment, and through 12 months post last dose of tagraxofusp for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluation of rate of response
Rate and severity of treatment-emergent adverse events

Trial Design

1Treatment groups
Experimental Treatment
Group I: Tagraxofusp (SL-401)Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SL-401
2014
Completed Phase 2
~220

Find a Location

Who is running the clinical trial?

Stemline Therapeutics, Inc.Lead Sponsor
18 Previous Clinical Trials
1,803 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you provide an overview of the additional experiments conducted with SL-401?

"SL-401 was first researched at University of California, Los Angeles in 2014. Since then two clinical trials have concluded and presently there are 7 active ones that take place predominantly in Duarte, Kansas."

Answered by AI

What risks have been identified with the administration of SL-401?

"Considering the Phase 2 status of SL-401, there is evidence to suggest that its safety can be quantified as a two on our team's scale. However, efficacy data is still required for further assessment."

Answered by AI

How many individuals can potentially partake in this experiment?

"This research endeavour necessitates the involvement of 130 eligible participants. Individuals can join this trial at either City of Hope in Duarte, Kansas or University of Kentucky Cancer Center in Westwood, Kentucky."

Answered by AI

How many medical sites are hosting this clinical experiment?

"At the moment, 10 different medical sites are recruiting for this trial. Locations include Duarte, Westwood and Louisville among other places. To minimise travel expenses associated with participation in the study it is best to opt for a clinic nearby."

Answered by AI

Is this research endeavor actively seeking participants?

"Clinicaltrials.gov shows that the trial, initially posted on December 1st 2014 and recently revised in April of 2022, is still recruiting participants."

Answered by AI
~8 spots leftby Mar 2025